The Effects of the Dietary Supplement CardioFlex Q10 on Reducing Cardiovascular Disease Risk Factors in Adults

Phase

N/A

Condition

Hypercholesterolemia

Coronary Artery Disease

Blood Clots

Treatment

N/A

Clinical Study ID

NCT03826914

CardioFLex Q10

Ages 30-65
All Genders
Accepts Healthy Volunteers

Study Summary

Cardiovascular diseases (CVD), primarily heart disease and stroke, are the leading causes of death and prescription drug use in Canada. Research on certain dietary supplements looks promising as a way to help reduce CVD risk factors. Studies show that supplementation of certain nutrients such as antioxidants, amino acids, electrolytes, vitamins and minerals may effectively reduce cardiovascular risk factors. The dietary supplement CardioFlex Q10, which is high in the aforementioned components, was developed to help regulate the body's production of cholesterol, strengthen the arteries and heart, and reverse oxidation.

The overall objective of this study is to determine if 90 days of supplementing with CardioFlex Q10 can reduce CVD risk factors in adults, independent of other dietary or physical activity changes.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Age 30-65
An accelerated plethysmograph (APG) type (biological age of arteries) of D, E, F or Gand/or a high density lipoprotein (HDL) to total cholesterol (TC) ratio of ≤24 percent

Exclusion

Exclusion Criteria:

Have used prescription cholesterol or blood pressure medication in the last 3 months
Perform more then 150 minutes of moderate to rigorous activity per week
Pregnant or planning on getting pregnant during the study period

Study Design

November 06, 2018

August 01, 2020

Study Description

The purpose of this study is to determine whether or not daily supplementation with the dietary supplement CardioFlex Q10 for 90 days can reduce cardiovascular risk factors in healthy adults. The health markers that will be tested include the participant's waist circumference, body weight, body mass index (BMI), atherosclerosis risk factors (blood pressure, plethysmogram (PTG) wave form, heart rate variability, accelerated plethysmograph (APG) type (biological age of arteries)), and blood work including total plasma lipid profile (total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides (TGs)), kidney and liver function (alanine aminotransferase (ALT), aspartate aminotransferase (AST), Lactate dehydrogenase (LDH), Blood Urea Nitrogen (BUN), creatinine), and inflammatory and endothelial function biomarkers (C-reactive protein (CRP), Interleukin-6 (IL-6), soluble intercellular cell adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) ).

All health markers will be tested the day before starting the study and the day after the study is completed.

Connect with a study center

Richardson Centre for Functional Foods and Nutraceuticals
Winnipeg, Manitoba R3T 6C5
Canada
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.